Key facts
- This page summarizes Hana Immunotherapeutics LLC's Form 3 filing for Zura Bio Ltd (ZURA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2023, 21:55.
Hana Immunotherapeutics LLC - 20 Mar 2023 Form 3 Insider Report for Zura Bio Ltd (ZURA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ZURA
- Reported as of
- 20 Mar 2023
- Net transaction value
- $0
- Reporting owner signature
- By: /s/ Chris Kim
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Hana Immunotherapeutics LLC filed Form 3 for Zura Bio Ltd (ZURA) on 04 Apr 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZURA
holding
Class A Ordinary Shares, par value $0.0001
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,404,274
- Date
- 20 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Received on March 20, 2023, as consideration pursuant to that certain Business Combination Agreement originally dated June 16, 2022 ("Business Combination Agreement"), by and among Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura"), JATT Acquisition Corp, a Cayman Islands exempted company ("JATT"), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT, JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT, and Zura Bio Holdings Ltd, a Cayman Islands exempted company (the "Business Combination"). The Reporting Person received the reported shares for its shares in Zura at the Exchange Ratio, as defined in the Business Combination Agreement, upon the closing of the Business Combination.
Footnote F2
The shares are held of record by Hana Immunotherapeutics LLC ("Hana"). Mr. Chris Kim is is the manager of Hana and as such has voting and investment power over the shares held by Hana. Mr. Kim disclaims beneficial ownership over all shares held by Hana over which he does not have a pecuniary interest.